Tigozertinib
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Tigozertinib
- DrugBank Accession Number
- DB19239
- Background
Tigozertinib (BLU-945) is currently under investigation in clinical trial NCT04862780 (Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC) for the treatment of NSCLC.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 556.7
Monoisotopic: 556.263188412 - Chemical Formula
- C28H37FN6O3S
- Synonyms
- 3-ISOQUINOLINAMINE, N-(2-((3S,4R)-3-FLUORO-4-METHOXY-1-PIPERIDINYL)-4-PYRIMIDINYL)-5-(1-METHYLETHYL)-8-((2R,3S)-2-METHYL-3-((METHYLSULFONYL)METHYL)-1-AZETIDINYL)-
- EGFR MUTANT-SELECTIVE INHIBITOR BLU-945
- N-{2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl}-5-(propan-2-yl)-8-[(2R,3S)-2-methyl-3-[(methanesulfonyl)methyl]azetidin-1-yl]isoquinolin-3-amine
- Tigozertinib
- External IDs
- BLU-945
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- PA4PTH5HL9
- CAS number
- 2660250-10-0
- InChI Key
- LIMFPAAAIVQRRD-BCGVJQADSA-N
- InChI
- InChI=1S/C28H37FN6O3S/c1-17(2)20-6-7-24(35-14-19(18(35)3)16-39(5,36)37)22-13-31-27(12-21(20)22)32-26-8-10-30-28(33-26)34-11-9-25(38-4)23(29)15-34/h6-8,10,12-13,17-19,23,25H,9,11,14-16H2,1-5H3,(H,30,31,32,33)/t18-,19+,23+,25+/m0/s1
- IUPAC Name
- SMILES
- CO[C@@H]1CCN(C[C@@H]1F)C1=NC=CC(NC2=CC3=C(C=CC(N4C[C@H](CS(C)(=O)=O)[C@H]4C)=C3C=N2)C(C)C)=N1
References
- General References
- Not Available
- External Links
- ChemSpider
- 115010209
- ChEMBL
- CHEMBL5095169
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data1, 2 Active Not Recruiting Treatment Adenocarcinomas / Antineoplastic Agents / Bronchial Neoplasm / Bronchogenic Carcinoma / Carcinoma / EGFR Activating Mutation / EGFR C797S / EGFR Exon 19 Deletion Mutation / EGFR Gene Mutations / EGFR L858R / EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance / EGFR Positive Non-small Cell Lung Cancer / EGFR T790M / Lung Disorder / Lung Neoplasm / Neoplasm / Neoplasms by Histologic Type / Neoplasms by Site / Neoplasms, Nerve Tissue / Non-Small Cell Lung Carcinoma / Protein Kinase Inhibitors / Respiratory Tract Diseases / Respiratory Tract Neoplasms / Thoracic Neoplasms 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at July 10, 2024 13:51 / Updated at July 11, 2024 07:56